In conclusion, our findings provide evidence for the effect of proliferation inhibition and apoptosis induction in CML cells by PPP2R5C knockdown, and such effects may particularly benefit developing a strategy including a combination of targeted therapy using TKIs for resistant cells. This evidence concerns the gene PPP2R5C and chronic myelogenous leukemia, BCR-ABL1 positive.